Takeda Pharma Files Forms for $3 Billion in New Senior Notes
Ticker: TKPHF · Form: 6-K · Filed: Jul 5, 2024 · CIK: 1395064
| Field | Detail |
|---|---|
| Company | Takeda Pharmaceutical Co Ltd (TKPHF) |
| Form Type | 6-K |
| Filed Date | Jul 5, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $1,100,000,000, $800,000,000, $600,000,000, $500,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-issuance, senior-notes, financing
TL;DR
Takeda just dropped filings for $3B in new debt across multiple maturities.
AI Summary
Takeda Pharmaceutical Company Limited filed a Form 6-K on July 5, 2024, to report the forms of several senior notes. These include $1.1 billion in 5.300% Senior Notes due 2034, $800 million in 5.650% Senior Notes due 2044, $600 million in 5.650% Senior Notes due 2054, and $500 million in 5.800% Senior Notes due 2064.
Why It Matters
This filing indicates Takeda is raising significant capital through debt issuance, which could fund operations, acquisitions, or debt refinancing.
Risk Assessment
Risk Level: low — This is a routine filing reporting the forms of previously announced debt issuances, not a material event.
Key Numbers
- $1.1B — Senior Notes due 2034 (Part of Takeda's debt issuance)
- $800M — Senior Notes due 2044 (Part of Takeda's debt issuance)
- $600M — Senior Notes due 2054 (Part of Takeda's debt issuance)
- $500M — Senior Notes due 2064 (Part of Takeda's debt issuance)
Key Players & Entities
- Takeda Pharmaceutical Company Limited (company) — Registrant
- $1,100,000,000 (dollar_amount) — Principal amount of 5.300% Senior Notes due 2034
- $800,000,000 (dollar_amount) — Principal amount of 5.650% Senior Notes due 2044
- $600,000,000 (dollar_amount) — Principal amount of 5.650% Senior Notes due 2054
- $500,000,000 (dollar_amount) — Principal amount of 5.800% Senior Notes due 2064
FAQ
What is the total principal amount of senior notes Takeda is reporting?
Takeda is reporting a total principal amount of $3 billion across four series of senior notes: $1.1 billion, $800 million, $600 million, and $500 million.
What are the interest rates and maturity dates for these senior notes?
The notes include $1.1 billion at 5.300% due 2034, $800 million at 5.650% due 2044, $600 million at 5.650% due 2054, and $500 million at 5.800% due 2064.
What type of filing is this for Takeda Pharmaceutical Company Limited?
This is a Form 6-K, which is a Report of Foreign Private Issuer pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.
When was this Form 6-K filed?
This Form 6-K was filed on July 5, 2024.
What specific exhibits are listed in this filing?
The filing lists Exhibit Numbers 4.1, 4.2, 4.3, and 4.4, which are the forms of the $1.1 billion, $800 million, $600 million, and $500 million Senior Notes, respectively.
Filing Stats: 295 words · 1 min read · ~1 pages · Grade level 7.1 · Accepted 2024-07-05 11:28:17
Key Financial Figures
- $1,100,000,000 — EXHIBIT Exhibit Number 4.1 Form of $1,100,000,000 5.300% Senior Notes due 2034 4.2 Form
- $800,000,000 — 300% Senior Notes due 2034 4.2 Form of $800,000,000 5.650% Senior Notes due 2044 4.3 Form
- $600,000,000 — 650% Senior Notes due 2044 4.3 Form of $600,000,000 5.650% Senior Notes due 2054 4.4 Form
- $500,000,000 — 650% Senior Notes due 2054 4.4 Form of $500,000,000 5.800% Senior Notes due 2064 5.1 Opini
Filing Documents
- form6k_070524.htm (6-K) — 14KB
- exhibit41_070524.htm (EX-4.1) — 69KB
- exhibit42_070524.htm (EX-4.2) — 69KB
- exhibit43_070524.htm (EX-4.3) — 69KB
- exhibit44_070524.htm (EX-4.4) — 69KB
- exhibit51_070524.htm (EX-5.1) — 12KB
- exhibit52_070524.htm (EX-5.2) — 21KB
- 0001395064-24-000107.txt ( ) — 325KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. TAKEDA PHARMACEUTICAL COMPANY LIMITED Date July 5, 2024 By s Norimasa Takeda Norimasa Takeda Chief Accounting Officer and Corporate Controller